Sara Pellegrino | Senior Vice President, Investor Relations and Corporate Communications |
Fred Vogt | Interim President and Chief Executive Officer |
Igor Bilinsky | Chief Operating Officer |
Jim Ziegler | Executive Vice President-Commercial |
Friedrich Finckenstein | Chief Medical Officer |
Jean-Marc Bellemin | Chief Financial Officer |
Raj Puri | Executive Vice President, Regulatory Strategy and Translational Medicine |
Peter Lawson | Barclays |
Michael Yee | Jefferies |
Tyler Van Buren | TD Cowen |
Colleen Kusy | Baird |
Yanan Zhu | Wells Fargo |
Reni Benjamin | JMP Securities |
Carolina Ibanez Ventoso | Stifel |
Asthika Goonewardene | Truist Securities |
Joe Catanzaro | Piper Sandler |
Mara Goldstein | Mizuho |
Kelsey Goodwin | Guggenheim |
Welcome to the Iovance Biotherapeutics’ Second Quarter 2023 Financial Results and Corporate Update Conference Call. My name is Shannon and I will be your operator for today’s call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Please note that this conference is being recorded.